C P Reynolds researcher
Reynolds, C. P.
Reynolds, Charles Patrick
VIAF ID: 1526428 (Personal)
Permalink: http://viaf.org/viaf/1526428
Preferred Forms
-
100 0 _
‡a
C P Reynolds
‡c
researcher
-
100 1 _
‡a
Reynolds, C. P.
-
100 1 _
‡a
Reynolds, Charles Patrick
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma |
|
| Metabolism of orthotopic mouse brain tumor models. |
|
| Microcomputer software and interface for control of a microscope scanning stage |
|
| Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target. |
|
| miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma |
|
| Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor |
|
| Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma |
|
| Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines |
|
| Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 |
|
| Multidrug resistance-associated protein 1 |
|
| N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase |
|
| N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. |
|
| N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). |
|
| N-myc protein expression in small round cell tumors |
|
| Neuroblastoma and nerve growth factor, 1979 |
|
| Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. |
|
| Novel cell lines established from pediatric brain tumors. |
|
| The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma |
|
| Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma |
|
| p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma |
|
| Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. |
|
| PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors |
|
| The pediatric preclinical testing program: description of models and early testing results. |
|
| Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. |
|
| Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma |
|
| Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial |
|
| Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation |
|
| Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas |
|
| Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study |
|
| Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group |
|
| Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. |
|
| Possible differential diagnosis of neuroblastoma from rhabdomyosarcoma and Ewing's sarcoma by using a panel of monoclonal antibodies |
|
| Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration |
|
| Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. |
|
| Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma |
|
| Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial |
|
| Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. |
|
| Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies. |
|
| Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads |
|
| Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. |
|
| Retinoid therapy of childhood cancer. |
|
| Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent children's cancer group results |
|
| Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant |
|
| Sensitive detection of neuroblastoma cells in bone marrow for monitoring the efficacy of marrow purging procedures |
|
| Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. |
|
| Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy |
|
| Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma |
|
| Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism |
|
| Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy |
|
| The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
|
| Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium |
|
| Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma |
|
| Telomerase activity by TRAP assay and telomerase RNA |
|
| Telomerase expression in primary neuroblastomas |
|
| Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma |
|
| Testing of new agents in childhood cancer preclinical models: meeting summary |
|
| Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. |
|
| Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. |
|
| Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference |
|
| Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. |
|
| Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines |
|
| Transplantation of human neuroblastoma cells, catecholaminergic and non-catecholaminergic: effects on rotational behavior in Parkinson's rat model |
|
| Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation |
|
| Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro |
|
